Sugi Predict

Sugi Predict / Targets / XIAP

XIAP

E3 ubiquitin-protein ligase XIAP · P98170 · XIAP on Sugi Atlas →

84,630 patent compounds predicted against XIAP, 47,753 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL40642 SCHEMBL40642 0.60 11/20
SCHEMBL159304 SCHEMBL159304 0.72 6/20
Embelin Embelin (SCHEMBL148744) 1.00 5/20
SCHEMBL157902 SCHEMBL157902 0.88 5/20
SCHEMBL157480 SCHEMBL157480 0.78 5/20
SCHEMBL157481 SCHEMBL157481 0.78 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL158501) 0.77 5/20
SCHEMBL158338 SCHEMBL158338 0.94 4/20
SCHEMBL158339 SCHEMBL158339 0.94 4/20
SCHEMBL156629 SCHEMBL156629 0.72 4/20
SCHEMBL172623 SCHEMBL172623 0.61 4/20
Ilepatril Ilepatril (SCHEMBL171139) 0.59 4/20
SCHEMBL159072 SCHEMBL159072 0.77 3/20
SCHEMBL157995 SCHEMBL157995 0.74 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL158745) 0.73 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL158746) 0.73 3/20
SCHEMBL158893 SCHEMBL158893 0.71 3/20
SCHEMBL156204 SCHEMBL156204 0.70 3/20
SCHEMBL175757 SCHEMBL175757 0.70 3/20
SCHEMBL175758 SCHEMBL175758 0.70 3/20

Clinical trials — most relevant to XIAP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis PHASE2COMPLETED
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) PHASE1/PHASE2COMPLETED
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer PHASE2COMPLETED
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma PHASE2WITHDRAWN
9-ING-41 in Patients With Advanced Cancers PHASE2ACTIVE_NOT_RECRUITING
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2RECRUITING
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) PHASE1/PHASE2WITHDRAWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies PHASE1/PHASE2COMPLETED
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma PHASE1COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma PHASE1COMPLETED
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer PHASE1UNKNOWN
Studying TAK-243 in Patients With Advanced Cancer PHASE1RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas PHASE1COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Establishment of a Prospective Clinical-biological Database nanRECRUITING
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage nanCOMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma nanACTIVE_NOT_RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a XIAP binder may also engage these)

ProteinNameSimilarity
Q9R0I6 — 1.000 Q9R0I6 →
BIRC3 Baculoviral IAP repeat-containing protein 3 0.997 landscape →
Q60989 — 0.996 Q60989 →
Q95M71 — 0.994 Q95M71 →
BIRC2 Baculoviral IAP repeat-containing protein 2 0.994 landscape →
Q5BKL8 — 0.994 Q5BKL8 →
A5D8Q0 — 0.993 A5D8Q0 →
Q62210 — 0.993 Q62210 →
Q90660 — 0.993 Q90660 →
A1E2V0 — 0.992 A1E2V0 →
O08863 — 0.992 O08863 →
BIRC8 Baculoviral IAP repeat-containing protein 8 0.991 landscape →
Q95M72 — 0.989 Q95M72 →
Q24307 — 0.988 Q24307 →
O62640 — 0.988 O62640 →
P41435 — 0.981 P41435 →
Q6R7I2 — 0.981 Q6R7I2 →
G5EFA2 — 0.980 G5EFA2 →
Q6R7E2 — 0.979 Q6R7E2 →
P41454 — 0.979 P41454 →
Q24306 — 0.979 Q24306 →
Q3T9Z9 — 0.978 Q3T9Z9 →
B1B1A0 — 0.977 B1B1A0 →
Q9H0M0 — 0.977 Q9H0M0 →
Q8T3Y0 — 0.977 Q8T3Y0 →
Q19546 — 0.977 Q19546 →
O93530 — 0.977 O93530 →
Q9FT70 — 0.977 Q9FT70 →
Q14149 — 0.977 Q14149 →
Q96AP4 — 0.976 Q96AP4 →